ILUMYA
-
Sun Pharma announces publication of ILUMYA’s five-year efficacy results
The results were announced at British Journal of Dermatology Sun Pharmaceutical Industries, USA (Sun Pharma) announced the publication of five-year…
Read More » -
Sun Pharma announces sustained efficacy for ILUMYA
ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase…
Read More »